| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.10 | 11.1% | 42.9% |
| Total Income | 0.10 | 11.1% | 42.9% |
| Expenditure | 3.20 | 17.9% | 58.0% |
| PBT | -2.90 | 19.2% | 49.6% |
| Net Profit | -3.01 | 16.2% | 47.7% |
| OPM | — | ||
| NPM | — | ||
| EPS | -3.51 | 4287.5% | 2600.0% |
Yarrow Bioscience Announces Merger Close with VYNE, Dosing in Phase 2a/2b Trial for YB-101
29 Jul 2026 · 29 Jul, 2:46 am
Summary
Yarrow Bioscience, Inc. announced the closing of its merger with VYNE Therapeutics Inc., and will now operate under the Yarrow Bioscience name, with shares trading on Nasdaq under 'YARW'. The company has initiated dosing in a Phase 2a/2b trial for its lead candidate YB-101 for Graves' disease, which has received FDA Fast Track Designation, with Phase 2a data anticipated in the second half of 2027. Additionally, data from a Phase 1 trial for YB-101 in thyroid eye disease are expected in the second half of 2027. The company has secured approximately $200 million in private financings, which are expected to fund operations into 2028.
Key Highlights
- 1
Yarrow Bioscience, Inc. announced the completion of its merger with VYNE Therapeutics Inc., with the combined company operating as Yarrow Bioscience, Inc.
- 2
The company has initiated dosing in a Phase 2a/2b trial evaluating its lead product candidate, YB-101, for Graves’ disease, with Fast Track Designation from the FDA.
- 3
Data from the Phase 2a portion of the Graves’ disease trial are expected in the second half of 2027.
- 4
Data from the ongoing Phase 1 multiple ascending dose trial of YB-101 in patients with thyroid eye disease in China are also expected in the second half of 2027.
- 5
Previously announced private financings totaling approximately $200 million are expected to fund operations into 2028.
- 6
Shares of the combined company's common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol 'YARW'.
Management Comments
Rebecca V. Frey
Yarrow is emerging with multiple value drivers anchored by YB-101, our potentially first-in-class anti-TSHR antibody, and the opportunity to address two significant market opportunities in GD and TED with a single product candidate. Current treatments for GD and TED are limited, and many carry serious toxicities or fail to directly address disease-driving TSHR signaling. YB-101 offers an entirely new treatment approach through TSHR blockade, which we believe is the most direct way to disrupt the underlying disease process and has the potential to meaningfully improve outcomes for patients living with GD and TED. With multiple clinical catalysts and cash runway into 2028, we believe Yarrow is well positioned to advance YB-101 and establish itself as a leader in thyroid autoimmune disease. We look forward to executing across our development program and advancing our mission to bring transformative therapies to patients.
Informational and educational content only. Not investment advice.